| Corixa | |
| Type: | biotechnology/pharmaceutical |
| Predecessors: | --> |
| Successor: | acquired by GlaxoSmithKline |
| Founded: | 1994 in Seattle, Washington |
| Founders: | --> |
| Hq Location City: | Seattle |
| Hq Location Country: | Washington |
| Num Locations: | 2 |
| Areas Served: | --> |
| Profit: | --> |
| Profit Year: | --> |
| Owners: | --> |
| Slogans: | --> |
| Homepage: | --> |
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.